Wei W, Yang H, Menconi M, Cao P, Chamberlain CE, Hasselgren P-O. Treatment of cultured myotubes with the proteasome inhibitor ␤-lactone increases the expression of the transcription factor C/EBP␤.
regulation of gene transcription varies in different physiological and pathological conditions. Previous studies suggest that the expression and activity of C/EBP␤ may be particularly important for gene regulation during inflammation (24) . In recent experiments, we found evidence that C/EBP␤ is involved in sepsis-and glucocorticoid-induced muscle wasting (23, 38) and in the inflammatory response in enterocytes (14) .
The transcriptional activity of C/EBP␤ may be influenced by posttranslational modifications, including phosphorylation (4) and acetylation (36) , as well as the formation of homodimers or heterodimers with other transcription factors (25) . An additional important factor that can influence the activity of C/EBP␤ is its cellular abundance. Similar to other C/EBP family members (7, 30, 31) , C/EBP␤ has a rapid turnover, and, in recent experiments, we found that the half-life of C/EBP␤ in cultured myotubes was ϳ1-2 h (34). The rapid turnover of C/EBP␤ is consistent with the tight control typically seen for many regulatory proteins and that is often accomplished by changes in the degradation of the proteins, although other mechanisms may be involved as well.
Different proteolytic mechanisms regulate the degradation and cellular levels of transcription factors. The ubiquitinproteasome proteolytic pathway plays an important role in the degradation of many cellular regulatory proteins, including transcription factors (12, 21) . Recent studies suggest that the degradation of some of the C/EBP family transcription factors, including C/EBP␣, -␥, and -␦ and Gadd153/CHOP, is proteasome dependent (7, 11, 30) . In contrast, the role of the proteasome system in the regulation of C/EBP␤ levels is controversial. Thus, whereas C/EBP␤ expression and activity were not influenced by proteasome activity in cultured keratinocytes (30) and human melanoma cells (11) , results from experiments in other cell types suggested that C/EBP␤ expression was regulated by the proteasome. For example, Yamamoto et al. (37) reported that the homolog of C/EBP␤ in the sea slug Aplysia californica, ApC/EBP, was degraded by the proteasome. In a recent study from our laboratory, treatment of cultured human enterocytes with the proteasome inhibitors MG-132 and lactacystin resulted in increased nuclear levels of C/EBP␤ (15) . Interestingly, this response to the proteasome inhibitors was, at least in part, caused by induction of the heat shock response. Thus it is possible that the role of the proteasome in the regulation of C/EBP␤ expression and activity is cell specific and may reflect different mechanisms.
In recent experiments, we found that the degradation of C/EBP␤ in cultured myotubes was calpain dependent (34) . This finding does not rule out that other mechanisms may be involved in the regulation of C/EBP␤ expression in muscle cells. Indeed, studies in other cell types suggest that multiple proteolytic pathways may contribute to the degradation of transcription factors (27) . The role of the proteasome in the regulation of C/EBP␤ levels in muscle cells is not known. Here, we tested the hypothesis that the degradation of C/EBP␤ in cultured myotubes is proteasome dependent.
MATERIALS AND METHODS
Materials. L6 rat skeletal muscle cells were purchased from American Type Culture Collection (Manassas, VA). DMEM was purchased from Mediatech (Herndon, VA). Clasto-lactacystin ␤-lactone was from Boston Biochem (Cambridge, MA). Calpeptin was from Calbiochem (San Diego, CA). Cycloheximide and quercetin were from Sigma (St. Louis, MO). Protein A/G PLUS-Agarose, oligonucleotide encoding the sequence for C/EBP binding, and a corresponding mutant oligonucleotide were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). NE-PER nuclear and cytoplasmic extraction reagents were from Pierce Biotechnology (Rockford, IL). In Situ Cell Death Detection Kit, TMR red, and DNase I recombinant, grade I were from Roche (Mannheim, Germany). [␥-
32 P]ATP and the Western Lightning Kit for enhanced chemiluminescence were purchased from Perkin-Elmer Life Sciences (Boston, MA). Poly(dI-dC) was from Boehringer Mannheim (Indianapolis, IN). Alexa Fluor 594 goat anti-mouse IgG and Alexa Fluor 488 goat anti-mouse IgG (2 mg/ml; Molecular Probes) as well as Oligofectamine Transfection Reagent were purchased from Invitrogen (Grand Island, NY). VECTASH-IELD Mounting Medium [with 4Ј,6-diamidino-2-phenylindole (DAPI)] was from Vector Laboratories (Burlingame, CA). Kodak X-Omat blue, X-Omat AR, and BioMax MR films were from Eastman Kodak (Rochester, NY). Minigels (10 and 12%) were purchased from Bio-Rad Laboratories (Hercules, CA). Coomassie plus protein assay reagent was from Pierce. Tri-Reagent was from Molecular Research Center (Cincinnati, OH). The TaqMan One Step PCR Master Mix Reagents Kit was from Roche Molecular Systems (Foster City, CA).
Plasmids and antibodies. siGENOME SMARTpool reagent (Rat DDIT3) and siCONTROL Non-Targeting small interfering RNA (siRNA) were purchased from Dharmacon (Chicago, IL). Mouse monoclonal antibodies to C/EBP␤ (H-7), Gadd153 (B-3), and 70-kDa heat shock protein (HSP 70; 3A3), rabbit polyclonal antibodies to C/EBP␤ (C-19), Gadd153 (F-168) and Oct-1 (C-12), and normal mouse IgG and normal rabbit IgG were from Santa Cruz Biotechnology. Monoclonal antibody to ␣-tubulin was from Sigma.
Cell culture. L6 rat skeletal muscle cells were thawed and maintained by repeated subculturing at low density in 162-cm 2 culture flasks and were used between passages 2 and 8. Cells were grown in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin in a 10% CO 2 atmosphere at 37°C. When cells reached ϳ80% confluence, they were removed by trypsinization (0.25% trypsin in PBS) and seeded in 10-cm culture dishes or six-well culture plates. The cells were grown in the presence of 10% FBS until they reached ϳ80% confluence at which time the medium was replaced with DMEM containing 2% FBS for induction of myotube differentiation. Cultures were used for experiments ϳ5 days later, when myotube formation was observed. Myotubes were treated with different concentrations of ␤-lactone, as indicated in RESULTS. Untreated myotubes served as controls. In separate experiments, 10 g/ml of cycloheximide or 5 g/ml of actinomycin D were added to the culture medium, either alone or in combination with 5 M ␤-lactone. After the different treatments, myotubes were harvested for determination of C/EBP␤, Gadd153/CHOP, and HSP 70 protein levels or DNA-binding activity, as described below.
Preparation of nuclear and cytoplasmic extracts and whole cell lysates. Nuclear and cytoplasmic fractions were prepared with Pierce NE-PER nuclear and cytoplasmic reagents according to the manufacturer's protocol (Pierce Biotechnology). NE-PER cytoplasmic extraction reagents (CER I and CER II) and nuclear extraction reagent enable the stepwise separation of cytoplasmic and nuclear extracts from cultured cells. In other experiments, whole cell lysates were prepared by lysing myotubes in three volumes of lysis buffer consisting of 50 mM Tris ⅐ HCl, pH 7.4, 300 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, and protease inhibitor cocktail. Protein concentrations in the nuclear extracts and whole cell lysates were determined by using the Pierce Coomassie blue R-250 method (Pierce Biotechnology) with BSA as standard.
Western blotting. Whole cell lysates or nuclear and cytoplasmic extracts were incubated at 100°C for 10 min, and aliquots (50 g protein) were loaded on 10 or 12% Bio-Rad polyacrylamide ready gels. The separated proteins were transferred electrophoretically using semidry transfer methodology to nitrocellulose membranes (Millipore). The membranes were treated with blocking buffer (5% nonfat dry milk, 20 mM Tris ⅐ HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween 20) for 1 h at room temperature. The membranes were then incubated overnight with the appropriate primary antibody, washed with 20 mM Tris ⅐ HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween 20 (TTBS) three times, and incubated for 1 h with the appropriate peroxidase-conjugated secondary antibody. ␣-Tubulin was determined as loading control for the cytoplasmic fraction and whole cell lysates. The transcription factor Oct-1 (28) was determined as loading control for the nuclear fraction. Membranes were then washed extensively in TTBS. Immunoreactive protein bands were detected by using the Western Lightning Kit for enhanced chemiluminescence and exposure on Kodak X-Omat blue or X-Omat AR film.
Coimmunoprecipitation. Coimmunoprecipitation was used to detect protein-protein interaction between C/EBP␤ and Gadd153/ CHOP. Aliquots (50 g protein) of whole cell lysates were immunoprecipitated with a rabbit polyclonal anti-C/EBP␤ (C-19) antibody or control IgG (nonimmune rabbit IgG) as well as with mouse monoclonal anti-Gadd153 antibody or control IgG (nonimmune mouse IgG) for 1 h at 4°C. After 1 h of mixing at 4°C, 25 l of packed Protein A/G PLUS-Agarose beads were added, and the samples were mixed at 4°C overnight. The beads were washed five times with 1 ml of buffer containing 50 mM Tris ⅐ HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% Nonidet P-40, and bound proteins were eluted with 2ϫ SDS sample buffer at 95°C for 5 min and were separated by 12% Bio-Rad polyacrylamide ready gels. Western blotting for C/EBP␤ or Gadd153/CHOP was performed as described above.
ATP and lactate dehydrogenase measurements. ATP was measured in control and ␤-lactone-treated myotubes using the commercially available CellTiter-Glo Luminescent Cell Viability Assay kit from Promega (Madison, WI). Lactate dehydrogenase (LDH) release from myotubes was measured using the CytoTox-ONE Homogeneous Membrane Integrity Assay kit from Promega.
Terminal deoxynucleotidyltransferase-mediated dUTP nick endlabeling assay. Apoptotic cell death was examined by terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL) assay and fluorescence microscopy (Nikon Eclipse TE300; Nikon, Avon, MA). Control (untreated) myotubes and myotubes treated with 5 M ␤-lactone for 6 h were fixed with 4% paraformaldehyde in PBS, pH 7.4, for 1 h at room temperature, rinsed with PBS, permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice, and washed two times with PBS. Staining was performed by incubating myotubes for 1 h at 37°C in a humidified atmosphere in the dark in 100 l of TUNEL reaction mixture (In Situ Cell Death Detection Kit, TMR Red, No. 12 156 792 001; Roche). Positive controls were obtained by treating permeabilized myotubes with DNase I, grade I (1,000 U/ml in 50 mM Tris ⅐ HCl, pH 7.5, and 1 mg/ml BSA), for 10 min at room temperature to induce DNA strand breaks before the staining procedure. Negative controls were per-formed by incubating fixed and permeabilized myotubes in 100 l/well of Label Solution (without terminal transferase) instead of TUNEL reaction mixture (data not shown).
Gadd153/CHOP siRNA. To reduce the expression of Gadd153/ CHOP, myotubes were transfected for 48 h with Gadd153/CHOP siRNA (siGENOME SMARTpool reagent; rat DDIT3), siCONTROL Nontargeting siRNA, or were mock transfected (treated with transfection reagents only without oligonucleotide). siRNA was diluted to 1.08 M in serum-free DMEM, and oligofectamine was diluted 1:5 in serum-free DMEM. These mixtures were incubated at room temperature for 5 min. The diluted lipid reagent was then added to the siRNA mixture and incubated a further 15 min at room temperature. The cells were rinsed one time with serum-free DMEM and bathed in serumfree DMEM. Lipid-RNA complexes were applied to the myotubes, and an equivalent amount of lipid reagent was added to mocktransfected myotubes. After transfection, myotubes were treated with ␤-lactone for 6 h or were untreated, whereafter Gadd153/CHOP levels were determined by Western blotting and C/EBP␤ DNA binding was determined by electrophoretic mobility shift assay (EMSA) with supershift analysis.
EMSA. C/EBP gelshift oligonucleotide (5Ј-TGC AGA TTG CGC AAT CTG CA-3Ј; Santa Cruz Biotechnology) was end labeled with [␥-
32 P]ATP using T4 polynucleotide kinase (GIBCO-BRL). Endlabeled probe was purified from unincorporated [␥-
32 P]ATP using a purification column (Bio-Rad Laboratories) and recovered in Tris-EDTA buffer, pH 7.4. Labeled DNA probe was incubated with 3 g of nuclear protein extracts (20 min, room temperature) in a buffer containing 12% glycerol (vol/vol), 12 mM HEPES, pH 7.9, 4 mM Tris ⅐ HCl, pH 7.9, 1 mM EDTA, 1 mM dithiothreitol, 25 mM KCl, 5 mM MgCl 2, and 0.04 g/l poly(dI-dC). An excess (15ϫ) of nonradiolabeled wild-type or mutant oligonucleotide (5Ј-TGC AGA GAC TAG TCT CTG CA; nucleotide substitutions underlined) was added to test the specificity of the EMSA. Supershift analysis was performed by adding 2 l of mouse monoclonal antibody to C/EBP␤, and the mixture was incubated at room temperature for 30 min. The resulting protein-DNA complexes were separated on a 7% polyacrylamide gel at 200 volts for 5 h. The gel was dried under vacuum for 2 h at 80°C, and protein-DNA complexes were visualized by autoradiography.
Localization and colocalization of C/EBP␤ and Gadd153/CHOP. L6 myotubes were cultured on German glass coverslips in six-well plates and treated with 1 or 5 M ␤-lactone for 6 h before fixation in 3.5% paraformaldehyde for 15 min. The fixed myotubes were permeabilized with 0.2% Triton X-100 for 10 min and incubated with mouse monoclonal antibody to C/EBP␤ (H-7) or mouse monoclonal antibody to Gadd153 (B-3) for 1 h at room temperature. After three washes in PBS containing 0.1% Tween, the coverslips were incubated with Alexa 594-conjugated goat anti-mouse secondary antibody for 1 h at room temperature. The coverslips were then washed three times in PBS containing 0.1% Tween and mounted on glass slides using DAPI mounting solution. Images were obtained using a Zeiss Laser Scanning Confocal Microscope 510 (Thornwood, NY) with ϫ40 objective. Background nonspecific fluorescence was determined by the same protocol in the absence of primary antibodies. All images were collected under identical settings.
To examine colocalization of C/EBP␤ and Gadd153/CHOP, the fixed L6 myotubes were permeabilized with 0.2% Triton X-100 and then incubated for 1 h with mouse monoclonal antibody to C/EBP␤ (H-7) and rabbit polyclonal antibody to Gadd153 (F-168) at room temperature and washed three times in PBS. Fluorescein Alexa 488-conjugated goat anti-mouse and Alexa 594-conjugated goat antirabbit secondary antibodies were added for 1 h and then rinsed with three washes of PBS. Cover slips were mounted with DAPI mounting solution. Immunofluorescence was detected using a Zeiss Laser Scanning Confocal Microscope 510 with ϫ40 objective. All images were collected under identical settings, and their respective backgrounds among the various conditions were tested in each experiment.
Statistical analysis.
Results are presented as means Ϯ SE. Statistical analysis was performed by using Student's t-test or ANOVA as appropriate. Experiments were repeated at least three times to provide evidence of reproducibility.
RESULTS
Several isoforms of C/EBP␤ have been described, including a full-length 38-kDa isoform [liver-enriched transcriptional activating protein (LAP)], a 35-kDa isoform of LAP, a 21-kDa liver-enriched transcriptional inhibitory protein (LIP), and a 14-kDa isoform (1, 8, 35) . Although the different C/EBP␤ isoforms are commonly thought to arise from alternative translational start sites in the coding sequence (8) , some studies suggest that the truncated 21-and 14-kDa isoforms of C/EBP␤ may be the result of artifactual proteolysis during tissue preparation (2, 3). Other reports suggest that truncated C/EBP␤ isoforms may be generated by both alternative translation and proteolytic cleavage of full-length C/EBP␤ (35) . In our experiments, the 35-kDa LAP was the predominant isoform in the cultured myotubes, whereas the expression of the 38-kDa full-length LAP and the 21-kDa LIP was lower and not detectable in some experiments. The 14-kDa isoform of C/EBP␤ was not detectable in any of our experiments. In the present study, when a certain isoform is not shown in Figs. 1-9, it reflects the fact that it was not detected in that experiment.
When cultured L6 myotubes were treated for 6 h with the specific proteasome inhibitor ␤-lactone (18), cellular levels of C/EBP␤ increased in a concentration-dependent manner (Fig.  1A) . The maximal effect was noticed at a ␤-lactone concentration of 5 M, and, at this concentration, the levels of all three C/EBP␤ isoforms expressed in the myotubes were increased. When myotubes were treated with 5 M ␤-lactone, C/EBP␤ levels increased after 3 h and were maximally increased after 6 h (Fig. 1B) . Treatment of the myotubes with 5 M ␤-lactone for 6 h did not induce appreciable cell injury. Thus there was no evidence of cell rounding or detachment (data not shown), and myotube ATP levels and LDH release were unaffected (Fig. 1, C and D) . In addition, TUNEL assay showed that the treatment did not result in apoptotic cell death, and phase-contrast microscopy revealed no apparent changes in myotube morphology (Fig. 2) . In most subsequent experiments, myotubes were treated with 5 M ␤-lactone for 6 h.
Increased C/EBP␤ levels in myotubes treated with ␤-lactone are consistent with proteasome-dependent degradation of C/EBP␤, although other mechanisms could be involved as well. To examine the influence of ␤-lactone on the degradation of C/EBP␤, the decrease in C/EBP␤ levels was determined in myotubes cultured in the presence of cycloheximide during 24 h. Because protein synthesis was blocked, the decrease in C/EBP␤ levels reflected degradation of the protein. To increase the accuracy of this experiment, myotubes were first treated with 1 M dexamethasone for 12 h to increase C/EBP␤ levels in the myotubes (38) . This allowed us to examine the degradation of C/EBP␤ in myotubes that contained high levels of the protein. Using this experimental approach, C/EBP␤ levels declined relatively rapidly in myotubes incubated in the absence of ␤-lactone (Fig. 3A) . When C/EBP␤ levels were quantified by densitometry (including both isoforms expressed in this experiment), results were consistent with a half-life of C/EBP␤ of ϳ2-4 h (Fig. 3B) . Treatment of the myotubes with ␤-lactone stabilized C/EBP␤ and prolonged the half-life to almost 24 h, suggesting that the proteasome inhibitor reduced the degradation of C/EBP␤.
Although the results reported here suggest that the increased C/EBP␤ levels noticed in ␤-lactone-treated myotubes reflected inhibited degradation of the transcription factor, increased expression of C/EBP␤ may also reflect increased synthesis of the protein. To test the potential role of protein synthesis in the ␤-lactone-induced increase in C/EBP␤ levels, the effect of the proteasome inhibitor was tested in myotubes incubated in the absence or presence of cycloheximide. In this experiment, basal levels of C/EBP␤ were reduced after 6 h treatment with cycloheximide (as expected), but even in these myotubes, an increase in C/EBP␤ levels was noticed after treatment with ␤-lactone (Fig. 4A) , suggesting that the ␤-lactone-induced increase in C/EBP␤ levels did not reflect stimulated synthesis. Additional experiments supported this interpretation. Thus treatment of the myotubes with the transcriptional inhibitor actinomycin D reduced basal levels of C/EBP␤ but did not prevent the ␤-lactone-induced increase in C/EBP␤ levels (Fig.  4B) . Somewhat unexpectedly, treatment of the myotubes with actinomycin D resulted in a more pronounced decrease in basal C/EBP␤ levels than treatment with cycloheximide (compare Fig. 4, A and B) . To test whether this effect of actinomycin D reflected cell toxicity, we determined the effect of actinomycin D on cell viability. Determined from LDH release, cell survival was not affected by treatment with 5 g/ml of actinomycin D for 6 h (Fig. 4C) .
One consequence of treatment with proteasome inhibitors is induction of the heat shock response (5) . In a recent study, we found that treatment of cultured human intestinal epithelial cells with the proteasome inhibitor MG-132 resulted in increased expression of heat shock protein 72 (HSP 72; see Ref. 15 ). In the same experiments, treatment of the cells with MG-132 increased C/EBP␤ levels, and this effect of the proteasome inhibitor was reduced by quercetin, a substance known to block induction of the heat shock response (20) . Those results suggested that the increased levels of C/EBP␤ in enterocytes treated with proteasome inhibitor were, at least in part, regulated by heat shock proteins. In the present study, treatment of the cultured myotubes with ␤-lactone for 6 h did not increase HSP 70 levels (Fig. 4D) . Because this finding does not rule out the possibility that other heat shock proteins were increased (16) and may have contributed to the increased C/EBP␤ levels, we treated myotubes with quercetin. Treatment of the myotubes with 100 M quercetin, a concentration that effectively inhibited the heat shock response in other cell types treated with proteasome inhibitors (15), did not prevent the ␤-lactone-induced increase in C/EBP␤ levels (Fig. 4E) , suggesting that the increased C/EBP␤ expression noticed in myotubes treated with ␤-lactone under the present experimental conditions was not regulated by the heat shock response. In fact, densitometric analysis of multiple experiments in which myotubes were treated with quercetin showed that C/EBP␤ expression was actually increased by ϳ15% in ␤-lactonetreated myotyubes when quecetin was added to the treatment (Fig. 4F ). This result further supports the interpretation that the ␤-lactone-induced increase in C/EBP␤ levels was not secondary to induction of the heat shock response. These results, however, do not rule out the possibility that the heat shock response may be induced and play a role in C/EBP␤ expression after more prolonged (Ͼ6 h) treatment of myotubes with ␤-lactone.
It should be noted that the experiments described above were performed in whole cell lysates. When C/EBP␤ expression was examined separately in the nuclear and cytoplasmic fractions, C/EBP␤ was detected almost exclusively in the nuclear fraction both in control and ␤-lactone-treated myotubes (Fig. 5A) . The separation of the nuclear and cytoplasmic fractions was confirmed by the expression of the transcription factor Oct-1 (28) in the nuclear fraction and ␣-tubulin in the cytoplasmic fraction. The nuclear localization and the effect of ␤-lactone treatment were also confirmed by immunofluorescent detection (Fig. 5B) .
Having shown that treatment of myotubes with ␤-lactone resulted in increased nuclear expression of C/EBP␤, we next examined the functional aspects of the observations and hypothesized that C/EBP␤ DNA-binding activity would be increased in ␤-lactone-treated myotubes. Surprisingly, EMSA with supershift analysis using an anti-C/EBP␤ antibody showed that C/EBP␤ DNA-binding activity was not increased in the ␤-lactone-treated myotubes (Fig. 6A, lane 3) . To make certain that this lack of C/EBP␤ DNA binding did not reflect a methodological error, we determined the effect of the calpain inhibitor calpeptin, a treatment that we found recently to increase C/EBP␤ expression and DNA-binding activity in cultured myotubes (34) . Treatment of the myotubes with 50 M calpeptin for 6 h resulted in increased C/EBP␤ DNAbinding activity (Fig. 6A, lane 2) . Interestingly, the increased C/EBP␤ DNA binding noticed in calpeptin-treated myotubes was blunted by ␤-lactone (Fig. 6A, lanes 2 and 4) . Of note was the finding that the lower bands in the EMSA were not substantially weaker when the supershifted band appeared (see Fig. 6A, lanes 2 and 4) . Although we do not have a definitive explanation for this finding at present, it is possible that the lack of a substantial decrease of the lower band reflects the fact that the C/EBP␤ antibody was added to the reaction in all four lanes in Fig. 6A . Hence, it is possible that there was a weak supershift present under basal conditions and that this supershift was too weak to generate a clear supershifted band but strong enough to reduce the lower band somewhat, making it more difficult to detect a difference in the lower band in Fig.  6A, lanes 2 and 4. As expected, the cellular levels of C/EBP␤ were increased in myotubes treated with ␤-lactone or calpeptin (Fig. 6B) . Interestingly, the effects of ␤-lactone and calpeptin on C/EBP␤ levels were additive, supporting the concept that the regulation of C/EBP␤ degradation is complex and may reflect the activity Fig. 2 . Effect of ␤-lactone on myotube morphology as seen by phase contrast microscopy (left) and apoptosis determined by terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) assay and detected by fluorescence microscopy after staining with TMR red as described in MATERIALS AND METHODS. Fixed and permeabilized myotubes were treated with DNase I as a positive control. In this assay, apoptotic nuclei stain bright red.
of multiple degradation mechanisms. It was interesting to note that C/EBP␤ DNA-binding activity was only increased to a small degree after the combined treatment with ␤-lactone and calpeptin (Fig. 6A, lane 4) despite a substantial increase in C/EBP␤ levels (Fig. 6B, lane 4) .
The lack of increased C/EBP␤ DNA binding noticed here in ␤-lactone-treated myotubes (despite the increased levels of the transcription factor) may reflect binding of C/EBP␤ to an inhibitory protein also increased by the ␤-lactone treatment. The C/EBP family members form complexes with other transcription factors, including other members of the C/EBP family. When Gadd153/CHOP interacts with other members of the C/EBP family, DNA binding is inhibited (6, 29) . Because experiments in other cell types showed that treatment with proteasome inhibitors results in increased expression of Gadd153/CHOP (11), it is possible that, in the present experiments, treatment of the myotubes increased the expression of the inhibitory Gadd153/CHOP, in addition to C/EBP␤, and that Gadd153/CHOP interacted with C/EBP␤ and inhibited its DNA-binding activity.
To examine the potential role of Gadd153/CHOP, we first determined the effect of ␤-lactone on myotube Gadd153/ CHOP levels. This was important because, although previous studies suggest that Gadd153/CHOP is degraded by a proteasome-dependent mechanism in other cell types (11) , the effects of proteasome inhibitors on Gadd153/CHOP levels in muscle cells have not been reported. Here we found that treatment of cultured L6 myotubes with ␤-lactone resulted in increased Gadd153/CHOP levels in the nuclear fraction (Fig. 7A) . The nuclear localization of Gadd153/CHOP and the effect of ␤-lactone treatment were confirmed by immunofluorescent detection (Fig. 7B) . Importantly, the Gadd153/CHOP levels were not influenced by calpeptin (Fig. 7, A and B) , similar to a recent report from our laboratory (34) .
We next tested whether treatment of the myotubes with ␤-lactone resulted in formation of heterodimers between C/EBP␤ and Gadd153/CHOP. Coimmunoprecipitation experiments provided evidence for an increased protein-protein interaction between C/EBP␤ and Gadd153/CHOP in the nuclear fraction of ␤-lactonetreated myotubes, consistent with the formation of heterodimers between the two transcription factors (Fig. 8, A and B) . Evidence for increased interaction between C/EBP␤ and Gadd153/CHOP was found both when an anti-C/EBP␤ antibody was used for pull down and an anti-Gadd153/CHOP antibody was used for immunoblotting (Fig. 8A ) and when the reversed order was used for coimmunoprecipitation (Fig. 8B) . Immunofluorescent detection showed that C/EBP␤ and Gadd153/CHOP colocalized to the same nuclei in ␤-lactone-treated myotubes, supporting the possibility that they interacted and formed heterodimers (Fig. 8C) .
To further test the role of increased Gadd153/CHOP levels in the lack of increased C/EBP␤ DNA binding in ␤-lactonetreated myotubes, we transfected myotubes with siRNA targeting Gadd153/CHOP mRNA. Other myotubes were transfected with nontargeting siRNA. The increase in Gadd153/CHOP levels caused by treatment with ␤-lactone was almost completely abolished in myotubes transfected with Gadd153/ CHOP siRNA but was not influenced by nontargeting siRNA (Fig. 9A ). When EMSA with supershift analysis was performed, results showed that C/EBP␤ DNA-binding activity was increased in ␤-lactone-treated myotubes in which the Gadd153/CHOP gene had been silenced (Fig. 9B, lane 6) but not in myotubes treated with non-targeting siRNA (Fig. 9B,  lane 5) . This result supports the concept that increased Gadd153/CHOP prevents C/EBP␤ DNA-binding activity in ␤-lactone-treated myotubes and may also explain why the increased C/EBP␤ DNA-binding activity seen in myotubes treated with calpeptin was blunted by ␤-lactone (see Fig. 6A,  lane 4) .
Although inhibited DNA-binding activity of C/EBP␤ is probably the most important consequence of the C/EBP␤-Gadd153/CHOP interaction, another possible consequence of the interaction could be that Gadd153/CHOP stabilized C/EBP␤ and prevented its degradation (in which case the increase in C/EBP␤ levels would be secondary to increased Gadd153/CHOP levels). To test that possibility, we determined C/EBP␤ levels in myotubes treated with Gadd153/CHOP siRNA. Downregulation of Gadd153/CHOP did not prevent the ␤-lactone-induced increase in C/EBP␤ levels (Fig. 9C,  lanes 3 and 4) despite the fact that the ␤-lactone-induced increase in Gadd153/CHOP was efficiently inhibited (see Fig.  9A, lanes 3 and 4) . This result argues against a model in which . Both the 38-and 35-kDa isoforms were included in the densitometric analysis. C/EBP␤ half-life was increased from 2-4 h to ϳ24 h by ␤-lactone. Results are means Ϯ SE with n ϭ 3 at each time point. Note that, in these experiments, the "0 h" myotubes had first been treated with 1 M dexamethasone for 12 h to increase the C/EBP␤ levels. This allowed for examination of the degradation of C/EBP␤ in myotubes containing high levels of the protein increasing the accuracy of the experiment. *P Ͻ 0.05 vs. CHX. increased C/EBP␤ levels after treatment with ␤-lactone were caused by stabilization of the protein by increased Gadd153/ CHOP levels.
DISCUSSION
In the present study, treatment of cultured myotubes with the specific proteasome inhibitor ␤-lactone resulted in a dose-and time-dependent increase in nuclear C/EBP␤ levels. Additional experiments showed that the stability of C/EBP␤ was increased in the presence of ␤-lactone and that the proteasome inhibitor increased C/EBP␤ levels independent of protein synthesis. Taken together, the results suggest that C/EBP␤ is degraded, at least in part, by a proteasome-dependent mechanism in skeletal muscle cells.
In previous studies, conflicting results were reported with regard to the role of the proteasome in the regulation of C/EBP␤ expression, possibly reflecting cell specificity. Thus, whereas evidence of proteasome-dependent degradation of C/EBP␤ was found in cultured intestinal epithelial cells (15) , hepatocytes (22) , lung fibroblasts (17) , and in the sea slug A. californica (37) , other studies suggested that C/EBP␤ degradation was not regulated by the proteasome in human melanoma cells (11) , keratinocytes (30), or preadipocytes (32) . To our knowledge, the present report is the first study examining the role of the proteasome in the degradation of C/EBP␤ in skeletal muscle cells.
In recent experiments, we found evidence that C/EBP␤ degradation was calpain dependent in cultured myotubes (34) . Taken together with those observations, the present results suggest that the degradation of C/EBP␤ is regulated by multiple proteolytic mechanisms in skeletal muscle. Because calpains typically cleave proteins into products that are subsequently further degraded by other mechanisms (10) , it is possible that C/EBP␤ is first cleaved by calpains and then degraded by the proteasome. Indeed, results in our recent report were consistent with the concept that calpain activity generates C/EBP␤ cleavage products, including the 21-kDa LIP, that are further degraded by the proteasome (34) . It should be noted, however, that the interaction between the calpain and proteasome systems in skeletal muscle is probably complex and may reflect not only a sequential cleavage and degradation of protein substrates. For example, in recent experiments, we found evidence that the two systems may be regulated in parallel, rather than in tandem, in sepsis-induced muscle wasting (9) . It should also be noted that, because the proteasome degrades proteins into small peptides rather than free amino acids, it is likely that additional proteolytic activities participate in the degradation of C/EBP␤ "downstream" of the proteasome. Interestingly, there is evidence that multiple proteolytic mechanisms regulate the degradation of other transcription factors as well, including c-Fos, c-Jun, and p53 (27) .
In contrast to the apparently conflicting reports on proteasome-dependent degradation of C/EBP␤, there is more uniform evidence that other members of the C/EBP family, including Gadd153/CHOP, are degraded by the proteasome (11, 30, 32) . In the present study, treatment of cultured myotubes with ␤-lactone resulted in increased nuclear expression of Gadd153/CHOP, consistent with proteasome-dependent degradation of Gadd153/CHOP in muscle cells. This observation is similar to results in other cell types in which treatment with various proteasome inhibitors resulted in increased Gadd153/CHOP levels (11, 32) .
Although Gadd153/CHOP has been reported to activate the transcription of certain genes, including genes referred to as DOCs (for downstream of CHOP; see Ref. 33 ), Gadd153/ CHOP more commonly acts as a dominant negative member of the C/EBP family by forming non-DNA-binding heterodimers with other C/EBP family members (6, 26, 29) . Because, in the present study, the increased nuclear levels of C/EBP␤ in ␤-lactone-treated myotubes were not associated with increased C/EBP␤ DNA-binding activity, we hypothesized that treatment of the myotubes with ␤-lactone resulted in increased levels of Gadd153/CHOP that inhibited C/EBP␤ DNA-binding activity. Our results did, indeed, support that hypothesis. Thus treatment of the myotubes with ␤-lactone resulted in increased levels of Gadd153/CHOP that colocalized and formed heterodimers with C/EBP␤ in the nuclei. Importantly, when the Fig. 5 . Effect of ␤-lactone on C/EBP␤ nuclear levels in cultured L6 myotubes. L6 myotubes were treated for 6 h with 1 or 5 M ␤-lactone followed by extraction of nuclear and cytoplasmic proteins and determination of C/EBP␤ levels by Western blotting (A) or determination of C/EBP␤ expression by immunofluorescent detection (B). In A, ␣-tubulin was used as loading control for the cytoplasmic fraction and Oct-1 as loading control for the nuclear fraction. ␤-lactone-induced increase in Gadd153/CHOP levels was prevented by Gadd153/CHOP siRNA, the increased C/EBP␤ levels resulted in increased DNA binding. A similar increase in Gadd153/CHOP levels and inhibition of C/EBP␤ DNA binding as observed here were reported recently in cultured preadipocytes treated with N-acetyl-Leu-Leu-norleucine, a nonspecific protease inhibitor that inhibits proteasome and calpain activities, further supporting the important role of interaction between C/EBP family members in the regulation of gene transcription (32) .
In contrast to the present study, increased C/EBP␤ levels caused by treatment of cultured enterocytes with the proteasome inhibitors MG-132 and lactacystin resulted in increased DNA-binding activity in a recent study from our laboratory (15) . Although Gadd153/CHOP levels were not measured in that study, the increase in C/EBP␤ DNA binding suggests that the Gadd153/CHOP expression was not increased in those experiments. Thus the role of the proteasome in the degradation of Gadd153/CHOP may be cell specific, similar to the regulation of C/EBP␤ degradation.
Although most proteins degraded by the proteasome are ubiquitinated (12) , some proteins, for example ornithine decarboxylase (13) , are degraded by the proteasome without prior ubiquitination. It is not known from the present experiments whether C/EBP␤ is ubiquitinated before being degraded by the proteasome. Previous studies suggest that other C/EBP family members, including C/EBP␣, C/EBP␥, and Gadd153/CHOP, are ubiquitinated before degradation (11, 30) . Interestingly, in a recent study by Kuang and Goldstein (17), treatment of cultured lung fibroblasts with MG-132 resulted in increased C/EBP␤ protein levels without generation of high-molecularweight, presumably ubiquitin-linked, forms of C/EBP␤, indicating that C/EBP␤ may be degraded by the proteasome without prior ubiquitination in lung fibroblasts.
The present study is important because it defined some of the potential mechanisms involved in the regulation of C/EBP␤ expression and activity in skeletal muscle. In previous studies, we observed that sepsis-and glucocorticoid-induced muscle wasting was associated with increased expression and activity of C/EBP␤ (23, 38) . Because several genes involved in the development of muscle wasting have putative C/EBP␤-binding sites in their promoter regions (23) , an increased understanding of mechanisms regulating C/EBP␤ expression and activity in skeletal muscle may have important clinical implications. It should be noted that, although the present and a recent report from our laboratory (34) suggest that C/EBP␤ proteins are degraded by both calpain-and proteasome-dependent mechanisms, it is not known at present which degradation mechanism is most important in physiological and pathological conditions. In sepsis-and glucocorticoid-induced muscle wasting, C/EBP␤ expression and DNA-binding activity are increased despite upregulated activity of both calpain-and proteasome-dependent protein degradation (23, 38) . Those observations suggest that the increased C/EBP␤ levels noticed in atrophying skeletal muscle during sepsis and glucocorticoid treatment reflect increased synthesis of C/EBP␤, an interpretation supported by increased C/EBP␤ mRNA levels in those conditions. Thus it is possible that, in various muscle-wasting conditions, the turnover of C/EBP␤ is stimulated with increased calpain-and proteasome-dependent degradation of C/EBP␤ and an even more pronounced increase in the synthesis of the transcription factor, resulting in a net increase in C/EBP␤ levels.
Because, in the present study, increased Gadd153/CHOP expression resulted in inhibited C/EBP␤ DNA-binding activity, it may be speculated that sepsis-and glucocorticoidinduced muscle wasting is not associated with a substantial increase in the expression of Gadd153/CHOP. It will be important in future studies to determine the influence of sepsis and other muscle-wasting conditions on the expression and activity of Gadd153/CHOP and its role in the regulation of C/EBP␤ DNA-binding activity.
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